Comprehensive ICD-10-CM Casefinding Code List for Reportable Tumors (Effective 10/1/2015-9/30/2016)
ICD-10-CM Code^ | Explanation of ICD-10-CM Code |
C00._ - C43._, C45._ - C96._ | Malignant neoplasms (excluding category ... |
C44.00, C44.09 | Unspecified/other malignant neoplasm of ... |
C44.10_, C44.19_ | Unspecified/other malignant neoplasm of ... |
C44.20_, C44.29_ | Unspecified/other malignant neoplasm ski ... |
Full Answer
Search the full ICD-10 catalog by:
The new codes are for describing the infusion of tixagevimab and cilgavimab monoclonal antibody (code XW023X7), and the infusion of other new technology monoclonal antibody (code XW023Y7).
The ICD-10-CM is a catalog of diagnosis codes used by medical professionals for medical coding and reporting in health care settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates.
ICD-10-CM Code for Malignant (primary) neoplasm, unspecified C80. 1.
ICD-10 code Z51. 11 for Encounter for antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Encounter for screening for malignant neoplasm of other sites. Z12. 89 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z12.
ICD-10-CM Code for Malignant neoplasm of brain, unspecified C71. 9.
Encounter for antineoplastic immunotherapyICD-10 code Z51. 12 for Encounter for antineoplastic immunotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
96413. Chemotherapy administration, intravenous infusion technique, up to 1 hour, single or initial substance drug.
Z12. 11: Encounter for screening for malignant neoplasm of the colon.
ICD-10 code Z12. 12 for Encounter for screening for malignant neoplasm of rectum is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
ICD-10 code: Z12. 4 Special screening examination for neoplasm of cervix.
Malignant neoplasm of brain, unspecified C71. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM C71. 9 became effective on October 1, 2021.
ICD-9 code 191.9 for Malignant neoplasm of brain unspecified site is a medical classification as listed by WHO under the range -MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED SITES (190-199).
C71. 1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM C71. 1 became effective on October 1, 2021.
11 or Z51. 12 is the only diagnosis on the line, then the procedure or service will be denied because this diagnosis should be assigned as a secondary diagnosis. When the Primary, First-Listed, Principal or Only diagnosis code is a Sequela diagnosis code, then the claim line will be denied.
Antineoplastic drugs are medications used to treat cancer. Other names for antineoplastic drugs are anticancer, chemotherapy, chemo, cytotoxic, or hazardous drugs.
ICD-10 Code for Encounter for antineoplastic chemotherapy and immunotherapy- Z51. 1- Codify by AAPC. Factors influencing health status and contact with health services. Encounters for other specific health care. Encounter for other aftercare and medical care(Z51)
Cyclophosphamide is used to treat cancer of the ovaries, breast, blood and lymph system, and nerves (mainly in children). Cyclophosphamide is also used for retinoblastoma (a type of eye cancer mainly in children), multiple myeloma (cancer in the bone marrow), and mycosis fungoides (tumors on the skin).
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes. Primary malignant neoplasms overlapping site boundaries.
Sarcoma is a malignancy that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a malignancy that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
Approximate Synonyms. Cancer distal third of esophagus, adenocarcinoma. Cancer of the esophagus, abdominal. Cancer of the esophagus, lower third. Primary adenocarcinoma of distal third of esophagus. Primary malignant neoplasm of abdominal esophagus. Primary malignant neoplasm of lower third of esophagus.
Primary malignant neoplasm of lower third of esophagus. Primary squamous cell carcinoma of lower third of esophagus. Squamous cell carcinoma, lower third of esophagus. Clinical Information. A primary or metastatic malignant neoplasm involving the lower third segment of the esophagus.
The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes. Primary malignant neoplasms overlapping site boundaries.
Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.
This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with CALs, from the Coding Analyses for Labs database.